Dicot Pharma AB (FRA:KN0) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KN0 Dicot Pharma AB FRA:KN0
23 GF Score
Price €0.01
! 2 Warning Signs
View Full Analysis

What is Dicot Pharma AB Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Dicot Pharma AB Quality Rank Related Terms

FRA:KN0
23GF Score
Dicot Pharma AB FRA:KN0
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dicot Pharma AB Business Description

Other Exchanges DICOT:SwedenKN0:Germany
Address S:t Olofsgatan 11A, Uppsala, SWE, SE 753 21
Dicot Pharma AB is developing a modern potency medicine that will treat erectile dysfunction and premature ejaculation than existing preparations. The business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. The company's drug candidate LIB-01 has a longer duration of action and fewer side effects, and is also used in the treatment of erectile dysfunction and premature ejaculation.
23GF Score

Get the complete analysis for FRA:KN0

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price